 Home > Active Ingredient News > Endocrine System > Cardiovasc Diabetol: The effect of empagliflozin on ketone body levels in patients with stable chronic heart failure

Cardiovasc Diabetol: The effect of empagliflozin on ketone body levels in patients with stable chronic heart failure

 Last Update: 2021-12-02
 Source: Internet
 Author: User

Tags

food cure diabetes

repaglinide 1 mg

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Recent studies have shown that sodium-glucose cotransporter 2 (SGLT-2) inhibitors can increase blood ketone levels in patients with type 1 and type 2 diabetes

Recent studies have shown that sodium-glucose cotransporter 2 (SGLT-2) inhibitors can increase blood ketone body levels in patients with type 1 and type 2 diabetes

In this prospective, double-blind, placebo-controlled, parallel-group single-center study, 75 CHF patients (left ventricular ejection fraction 39.

The main finding of this study is that compared with the placebo group, in patients with stable CHF, treatment with emgliflozin for 12 weeks resulted in an increase in fasting serum β-OHB

Compared with the placebo group, in patients with stable CHF, treatment with engligliflozin for 12 weeks resulted in an increase in fasting serum β-OHB

Englitazone oxazin treatment 12 weeks after treatment and placebo 12 Room Zhou Houji line β- hydroxybutyrate (β-OHB) change ( left )

In the current study, it was found that the improvement of blood vessel stiffness and blood pressure was negatively correlated with the increase of serum β-OHB, indicating that the increase of β-OHB was related to the lower improvement of central blood pressure and 24-hour ABP

It was found that the improvement of vascular stiffness and blood pressure was negatively correlated with the increase of serum β-OHB, indicating that the increase of β-OHB was related to the lower improvement of central blood pressure and 24-hour ABP

beta] - Relationship between hydroxybutyrate, blood pressure and vascular parameters

Interestingly, the results of the study showed that the increase in β-OHB had a negative effect after treatment with emglitazone, and ketone bodies increased in patients with stable CHF after taking emglitazone

In patients with stable CHF, ketone bodies increase after taking emglitazone

Pietschner, R.
, Kolwelter, J.
, Bosch, A.
et al.
Effect of empagliflozin on ketone bodies in patients with stable chronic heart failure.
Cardiovasc Diabetol 20,219 (2021).
https://doi.
org/10.
1186/ s12933-021-01410-7 https://doi.
org/10.
1186/s12933-021-01410-7 Leave a message here

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.